|
|
|
|
Vol. 19, Issue 6, 2433-2443, June 2008
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Department of Biological Sciences, University of Illinois at Chicago, Chicago, IL 60607
Submitted January 25, 2008;
Revised February 20, 2008;
Accepted March 10, 2008
Monitoring Editor: Jonathan Weissman
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
In [psi–] cells, the essential Sup35 protein is monomeric, and it is required for termination of protein synthesis at stop (nonsense) codons (for review, see Inge-Vechtomov et al., 2003
). In [PSI+] cells that bear the aggregated, partially inactive prion form of Sup35, protein synthesis continues beyond some nonsense codons at an increased rate. Such nonsense codon readthrough is routinely assayed as nonsense suppression (see Chernoff et al., 2002
). Analogously to the strains of the PrPsc prion, the [PSI+] prion has different "variants" (Derkatch et al., 1996
), which result from differences in the amyloid conformation of Sup35 monomers, variations in the arrangement of the monomers within polymers, or both (King and Diaz-Avalos, 2004
; Tanaka et al., 2004
; Diaz-Avalos et al., 2005
; Krishnan and Lindquist, 2005
; Tessier and Lindquist, 2007
; Toyama et al., 2007
). The efficiency of [PSI+] nonsense suppression is variant-specific and correlates with the degree of Sup35 aggregation. Cells that bear "strong" [PSI+] variants contain mostly aggregated Sup35 and exhibit high levels of nonsense suppression. Cells that bear "weak" [PSI+] variants contain more nonprionized Sup35, and exhibit lower levels of nonsense suppression (Derkatch et al., 1996
; Zhou et al., 1999
).
The prion properties of Sup35 are dictated by its 124-amino acid-long asparagine- and glutamine-rich N-terminal (N) domain (Ter-Avanesyan et al., 1994
; DePace et al., 1998
; Liu and Lindquist, 1999
; Chernoff et al., 2000
; Santoso et al., 2000
; Parham et al., 2001
; Bradley and Liebman, 2004
; Ross et al., 2005
). The N and the following M (amino acids 125–254) regions are dispensable for the activity of Sup35 in translational termination, which is carried out by its conserved C-terminal domain (Ter-Avanesyan et al., 1993
). In vitro, the recombinant full-length Sup35 (Glover et al., 1997
; Krzewska and Melki, 2006
; Shorter and Lindquist, 2006
) or its N-terminal prion domain alone (King et al., 1997
; Paushkin et al., 1997
; Serio et al., 2000
; Krzewska et al., 2006
; Shewmaker et al., 2006
; Vitrenko et al., 2007
) form amyloid fibers, which grow by recruiting Sup35 monomers (Scheibel et al., 2001
; Collins et al., 2004
) (but see Narayanan et al., 2006
). Amyloid fibers of the N-terminal domain of Sup35 made in vitro are infectious and they induce [PSI+] when delivered into [psi–] cells (King and Diaz-Avalos, 2004
; Tanaka et al., 2004
).
In vivo, [PSI+] transmission occurs during budding when the daughter cell acquires a portion of mother's cytoplasm containing one or more "seeds" with Sup35 in the prion form. Seeds in the daughter cell then recruit nonprionized Sup35 molecules and convert them into the prion fold (Satpute-Krishnan and Serio, 2005
). Experimental data support the idea that the Sup35-containing aggregates (Paushkin et al., 1996
) that quickly sediment from yeast lysates upon centrifugation (see Serio et al., 1999
) are the authentic [PSI+] seeds (Satpute-Krishnan and Serio, 2005
). When treated with SDS at room temperature, the aggregates decrease in size
30-fold and yield smaller, SDS-stable polymers of Sup35 (Kryndushkin et al., 2003
; Bagriantsev and Liebman, 2004
). Based on these observations it was suggested that the aggregates are organized at two-levels: SDS-stable polymers of Sup35 binding to each other directly, or via other unknown proteins, through less stable SDS-sensitive interactions (Kryndushkin et al., 2003
).
The de novo appearance and subsequent propagation of [PSI+] (Park et al., 2006
) (as well as [PIN+] and [URE3]) are tightly controlled by chaperones (for review, see Jones and Tuite, 2005
; Chernoff, 2007
). The ribosome-associated proteins Ssb1 and Ssb2 (Ssb1/2) antagonize the de novo appearance of [PSI+] (Chernoff et al., 1999
; Allen et al., 2005
), possibly by preventing the nascent Sup35 polypeptide from adopting the prion fold. Once [PSI+] is established, it requires Hsp104 for propagation (Chernoff et al., 1995
). Hsp104, with the help of other chaperones, disaggregates denatured proteins (Glover and Lindquist, 1998
), and it is believed to use this disaggregating activity (with or without the help of other chaperones) to propagate [PSI+] seeds (Inoue et al., 2004
; Krzewska and Melki, 2006
; Shorter and Lindquist, 2006
). Ssa1 and Ssa2 (Ssa1/2), possibly with the help of its Hsp40 cochaperones (e.g., Sis1 and Sse1), seems to stabilize [PSI+] propagation (for latest examples, see Jones et al., 2004
; Allen et al., 2005
; Loovers et al., 2006
; Fan et al., 2007
; Kryndushkin and Wickner, 2007
). Several experiments have shown that the balance of different chaperones can affect [PSI+] appearance, propagation, or both. For example, overexpression of Ssa1/2 antagonizes (Newnam et al., 1999
) the [PSI+]-curing effect of Hsp104 overexpression (Chernoff et al., 1995
), whereas overexpression of Ssb potentiates it (Chernoff et al., 1999
). Although many aspects of the prion–chaperone interactions remain unclear, evidence indicates that the yeast prions exploit the chaperone machinery for their own propagation. A recent study demonstrated that chaperones are associated with toxic polyglutamine aggregates in a yeast model of Huntington's disease (Wang et al., 2007
). Chaperones are therefore the most obvious candidates as components of yeast prion aggregates, including [PSI+].
Indeed, it was shown that Rnq1, the prion component of [PIN+] aggregates, exists in the cytosol in an
1:1 complex with Sis1, and it also interacts with Ssa1/2 and Ydj1 (Sondheimer et al., 2001
; Lopez et al., 2003
; Aron et al., 2007
). Likewise, a physical association between Sup35 and the members of the yeast Hsp70 family Ssa1/2 and Ssb1 was shown in vitro and in lysates from yeast overexpressing Sup35 (Allen et al., 2005
; Krzewska and Melki, 2006
; Allen et al., 2007
). Although some chaperones (e.g., Hsp104) may affect different yeast prions similarly (Chernoff et al., 1995
; Moriyama et al., 2000
; Sondheimer and Lindquist, 2000
; Derkatch et al., 2001
), the effects of others (e.g., Ssa1/2) are specific to a particular prion (Schwimmer and Masison, 2002
; Kryndushkin and Wickner, 2007
), suggesting that the same chaperones are not necessarily components of all the yeast prion aggregates.
Understanding the protein composition of prion aggregates may be important for uncovering the molecular mechanism by which prions propagate their variant-specific conformation from cell to cell. Although successful propagation of the same prion variant does not seem to require other proteins in vitro, the in vivo mechanism may involve chaperones, at least for some prions. For example, mutations in Sis1 alter the Rnq1–green fluorescent protein fluorescence pattern in [PIN+] cells (Sondheimer et al., 2001
; Lopez et al., 2003
) in a way that resembles a switch from one [PIN+] variant to another (Bradley and Liebman, 2003
). Although a similar phenomenon has not been reported for [PSI+], it was shown that different variants of [PSI+] may respond differently to overproduced chaperones (Kushnirov et al., 2000b
), suggesting that chaperones may control some [PSI+] variants while having no effect on others, and that the protein composition of [PSI+] aggregates may differ among [PSI+] variants. In this study, we examined the morphology of different variants of [PSI+] aggregates isolated from yeast, identified the protein components of these aggregates, and analyzed the requirement of their structural integrity for variant-specific [PSI+] infection.
| MATERIALS AND METHODS |
|---|
|
|
|---|
::LEU2 derivative of 74D-694 bearing a strong variant of [PSI+] and expressing full-length Sup35 from a pRS313-based CEN HIS3 plasmid under the natural SUP35 promoter (L2979) was a gift from C. G. Crist and Y. Nakamura (Crist et al., 2003
Bal2 (p747) plasmid (a gift from Inge-Vechtomov; Ter-Avanesyan et al., 1993
Strong [PSI+] and [psi–] sup35
NM strains bearing N(1-137) were constructed as described previously (Bradley and Liebman, 2004
). Briefly, a [psi–] [rho–] sup35
2-254 (sup35
NM) derivative of 74D-694 (L2275) bearing the N(1-137) domain of Sup35 under the natural SUP35 promoter on a centromeric vector (p1328), was cytoduced with [psi–] (L2198) or strong [PSI+] (L2200) [RHO+] [pin–] derivatives of the yeast strain A3099 (MAT
ade2-1 SUQ5 lys1-1 his3-11,15 leu1 ura3::kanMX4 kar1-1), and the [RHO+] [PSI+] and [RHO+] [psi–] cells bearing the genotype of L2275 were selected as described previously (Bradley and Liebman, 2004
).
Isolation of [PSI+] Aggregates
Cells were grown in 500 ml of complex medium to an optical density of
3.0 at 600 nm, harvested (
2.5 g of wet pellet), washed in lysis buffer (LB: 25 mM Tris-HCl pH 7.6, 50 mM KCl, 5 mM MgCl2, 10 mM imidazole, and 5% glycerol), harvested, resuspended in 15 ml of LB supplemented with antiproteases (10 mM phenylmethylsulfonyl fluoride plus 1.25% of the antiprotease cocktail for isolating histidine-tagged proteins; Sigma-Aldrich, St. Louis, MO), and lysed by violent agitation with 12 ml of 0.5-mm glass beads using a BeadBeater (BioSpec Products, Bartlesville, OK) for 40 s at 4°C. Crude lysate was centrifuged at 4500 x g (4°C) for 10 min followed by filtration through a 1-µm glass filter (GE Osmonics, Minnetonka, MN) to remove cellular debris. Five milliliters of lysate containing 5 mg of total protein (determined using the Bradford reagent from Bio-Rad, Hercules, CA) (Bradford, 1976
) was subjected to centrifugation on top of a sucrose cushion (5 ml of 30% over 5 ml of 60%, wt/vol, sucrose in LB) for 1 h at 27,000 rpm (15°C) by using the SW27 rotor (Beckman Coulter, Fullerton, CA). The majority of the soluble proteins did not penetrate into the 30% sucrose layer (data not shown). The top 2.5 ml of the 30% sucrose layer containing [PSI+] aggregates (determined by immunoblotting with a-Sup35C antibody, see below; data not shown) were incubated in a chromatography column with 1 ml of 1:1 LB slurry of the Co2+-charged Talon resin (Clontech, Mountain View, CA) for 15 min at room temperature. The liquid phase was drained and the resin was washed with 3.5 ml of LB. The proteins were eluted with 600 µl of 30 mM Tris-HCl, pH 7.6, containing 50 mM KCl, 50 mM ethylenediamine tetraacetate-Na, and 1% of the antiprotease cocktail. For electron microscopy analysis and prion transformation, the resin was additionally washed with 7.5 ml of LB and 15 ml of PBSM buffer (1.5 mM KH2PO4, 2.7 mM Na2HPO4, pH 7.2, 155 mM NaCl, 10 mM imidazole, 5 mM MgCl2, and 5% glycerol), and eluted with PBSM supplemented with 200 mM imidazole. The eluate was concentrated by centrifugation through a 100-kDa molecular weight cut-off filter (Biomax Ultrafree; Millipore, Billerica, MA). Analysis of the eluate by SDS-electrophoresis in agarose and immunoblotting (see below) showed that the sizes of the SDS-stable Sup35 polymers in the initial unfractionated lysate and final fraction (eluate) were the same (Supplemental Figure S2), indicating that we obtained a representative fraction of Sup35 molecules.
Immunocapture on Magnetic Beads
Yeast were grown in 50 ml of complex medium to an optical density of
3.0 at 600 nm, harvested, and washed in protein extraction buffer (PEB: 40 mM Tris-HCl, pH 7.6, 150 mM KCl, 5 mM MgCl2, and 5% glycerol). Cells were resuspended in 800 µl of PEB containing the Sigma anti-protease cocktail with phenylmethylsulfonyl (see above), and then they were disrupted by vortexing in a 1.5-ml tube with 750 µl of 0.5-mm glass beads. The crude lysate was precleared by centrifugation for 10 min at 10,000 x g at 4°C. KCl and Triton X-100 were added to precleared lysates to final concentrations of 350 mM and 1%, respectively. Five hundred to 800 µl of lysates (0.5–1.0 mg/ml) was mixed with 0.5 µl of
-Ssa1/2, or 4.0 µl of
-his6, or 5 µl of
-HA, or 10 µl of
-Hsp104 antibody (see below) and incubated for 2 h on ice. After incubation, 50 µl of magnetic beads with immobilized G protein (Miltenyi Biotec, Auburn, CA) were added, and the samples were further incubated on ice for 1 h. To remove nonspecifically bound proteins, the beads were washed with 1.0 ml of PEB, 150 mM KCl, 1% Triton X-100 (at 4°C), and with 1.0 ml of each of the following solutions and in the following order (at room temperature): PEB, 1% Triton X-100; PEB with 500 mM NaCl, 1% Triton X-100; PEB with 1% Triton X-100; and Tris-HCl, pH 7.6 (500 µl). Proteins were eluted with hot sample buffer (50 mM Tris-HCl, pH 6.8, 5% glycerol, and 0.05 and 2% β-mercaptoethanol), and then they were analyzed by electrophoresis and immunoblotting (see below). To check the stability of proteins during incubation, we incubated lysates (without antibodies) along with the experimental samples.
Electrophoresis and Immunoblotting
Samples were treated with sample buffer (50 mM Tris-HCl, pH 6.8, 5% glycerol, and 0.05% bromphenol blue for acrylamide, or with 25 mM Tris, 200 mM glycine, 5% glycerol, and 0.05% bromphenol blue for agarose gels) containing 2% SDS, for 7 min at 95°C or at room temperature and resolved by SDS-electrophoresis in polyacrylamide (Serio et al., 1999
) or agarose (Bagriantsev et al., 2006
) gels. Protein bands were detected by Coomassie G250 (Bio-Rad). Densitometry of Coomassie-stained protein bands was performed using an Alpha Imager 2200 (Alpha Innotech, San Leandro, CA) and processed on AlphaEaseFC imaging software. The same software was used to calculate the position of the 1500-kDa marker in Supplemental Figures S1B and S2. For immunoblotting, the proteins were electrophoretically transferred from the gels to an Immun-Blot polyvinylidene difluoride membrane (Bio-Rad) and detected with respective antibody (see below) by using a Western-Star chemiluminescence development kit (Applied Biosystems, Foster City, CA) as suggested by the manufacturer.
Antibodies
The following antibodies were used:
-Sup35C (BE4, mouse monoclonal against Sup35C (Bagriantsev and Liebman, 2006
);
-Rnq1 (type II, rabbit polyclonal),
-Sup35N (Ab0332, rabbit polyclonal against amino acids 55-68 of Sup35), gifts from S. Lindquist;
-Ssa1/2 (SSA1/2 C1
B, rabbit polyclonal against the last 56 amino acids of Ssa1 (Lopez-Buesa et al., 1998
),
-Ssb1 (rabbit polyclonal against the last 80 amino acids of Ssb1),
-Sis1 (rabbit polyclonal against full length Sis1; Yan and Craig, 1999
), gifts from E. Craig;
-Sse1 (rabbit polyclonal against amino acids 663-684 of Sse1; Goeckeler et al., 2002
), a gift from L. Brodsky;
-Sla2 (rabbit polyclonal against amino acids 664-968; Yang et al., 1999
), a gift from D. Drubin;
-Hsp104 (SPA-1040, rabbit polyclonal against amino acids 894-908 of Hsp104; Assay Designs, Ann Arbor, MI); and
-polyhistidine (sc-803, rabbit polyclonal) and
-Ydj1 (sc-23749, goat polyclonal) were from Santa Cruz Biotechnology;
-hemagglutinin (HA-7, mouse monoclonal; Sigma-Aldrich).
Electron Microscopy
Samples (4–6 µl) were applied onto Formvar carbon-coated copper grids (FCF2010-Cu from Electron Microscopy Sciences), incubated for 3 min, washed with water three times, and stained with 2–2.5% aqueous uranyl acetate (Ted Pella, Redding, CA) for 90 s. Images were obtained using a JEOL JEM-1220 transmission electron microscope operating at 80 kV. Micrographs were collected using a Gatan digital camera. Data from three S [PSI+], three control [psi–], and one control S [PSI+] wild-type (wt) isolations were analyzed. Each sample was applied onto several grids, and the whole visible area on at least two grids from each sample was examined. The structures shown in Figure 5 were found in S [PSI+], but not in the control samples.
Prion Transformation
Transformation was performed as described previously (Tanaka et al., 2004
) with modifications (Patel and Liebman, 2007
). Briefly, a [psi–] derivative of 74D-694 sup35
expressing Sup35 from a plasmid was grown to an optical density of 0.65 and transformed with a URA3 plasmid (pRS316) mixed with 15 µl of a [PSI+] aggregate preparation from L2988 or L2982, or mock aggregate preparation from L2983 or L2979. Ura+ transformants were selected and transferred to complex and adenine-deficient medium to find nonsense suppressors ([PSI+] candidates). Because the ADE1 gene (required for adenine synthesis) in 74D-694 is represented by the ade1-14 nonsense allele, [psi–] cells are Ade– due to termination of Ade1 synthesis at the premature stop codon, and they are red on complex medium due to accumulation of a red intermediate of the adenine synthesis pathway. In [PSI+] cells, the premature nonsense codon of ade1-14 is suppressed, which makes the yeast Ade+ and white (see Chernoff et al., 2002
), as shown in Supplemental Figure S1A. To confirm that the nonsense suppressor phenotype was caused by [PSI+], Ade+ cells ([PSI+] candidates) were transferred to complex medium supplemented with 5 mM guanidine hydrochloride. Cells that were Ade+ and red on complex medium (lacking guanidine) after growth on guanidine were scored as [PSI+]. The efficiency of prion induction was calculated as a proportion of [PSI+] cells relative to the initial number of Ura+ transformants.
Mass Spectrometry Analysis
Identification of the 70-kDa band was performed at the Proteomics and Informatics Services Facility (University of Illinois, Chicago, IL). The band was excised from the gel, digested with trypsin, and analyzed by capillary-liquid chromatography tandem mass spectrometry using the LTQ FT Ultra hybrid mass spectrometer (Thermo Electron, Waltham, MA). The database searches were performed using the Mascot (Matrix Science, Boston, MA) and Sequest (Thermo Electron) programs.
| RESULTS |
|---|
|
|
|---|
) expressing a hexahistidine(his6)-tagged Sup35 from a centromeric vector under the natural SUP35 promoter, with or without either a weak (W) or strong (S) [PSI+] variant. As shown previously (Ness et al., 2002
4–20 Sup35 monomers before and after purification (Supplemental Figure S2). The protein components of the partially purified aggregates were separated by SDS-polyacrylamide gel electrophoresis (PAGE) and visualized by Coomassie G250 staining after treatment with SDS at room temperature (to disassemble [PSI+] aggregates but preserve Sup35 polymers), or at 95°C (to further monomerize Sup35 polymers). We hypothesized that the aggregates would contain SDS-stable Sup35 polymer(s) with other protein(s) bound to the polymers via regular (i.e., sensitive to SDS treatment at room temperature) protein–protein interactions.
|
2 times more abundant than Ssa1/2 in W and S [PSI+] aggregates (Figure 1C).
We confirmed the identities of the Coomassie-stained Sup35 and Ssa1/2 bands (Figure 1, B and C) by immunoblotting with respective antibodies (Figure 2A). To detect minor components of [PSI+] aggregates, which were not revealed by Coomassie staining, we undertook a candidate approach and analyzed the aggregates by immunoblotting (Figure 2B). We found that Sla2 (Ganusova et al., 2006
), Hsp104 (Figures 2B and Supplemental Figure S3), as well as cochaperones Sis1, Sse1, and Ydj1 of Ssa1/2 were coisolated with Sup35 from W and S [PSI+], but not from control Swt[PSI+] yeast (Figure 2B). Ssb1, which was previously shown to interact with Sup35 (Allen et al., 2005
), was also coisolated with Sup35, but we consistently detected some Ssb1/2 in control isolations. Sup35 aggregate preparations from our [pin–] strains did not contain any detectable amounts of Rnq1, which is itself aggregated into a prion only in [PIN+] strains. Thus, our data suggest that aggregates of different [PSI+] variants have a similar protein composition and mostly contain Sup35 and Ssa1/2, plus some minor components, among which we found Hsp104, Sse1, Sis1, Ydj1, Sla2, and Ssb1/2, but not Rnq1.
|
-his6 or
-Ssa1/2 antibodies. To avoid the bias toward isolating heavy protein aggregates due to the use of centrifugation in conventional immunoprecipitation technique, we instead pulled the antibodies from lysates via protein G-coupled magnetic beads. After washing the beads, we analyzed the coisolated proteins for the presence of Sup35 and Ssa1/2 by immunoblotting. Consistent with the data shown on Figure 1, Ssa1/2 was specifically coisolated with Sup35 from unfractionated W and S [PSI+] lysates via both
-Ssa1/2 and
-his6 antibody (Figure 3). However, the interaction between Ssa1/2 and the nonprion form of Sup35 from [psi–] lysates was very inefficient (yet detectable), although both
-his6 and
-Ssa1/2 pulled out their antigens. The cellular levels of Ssa1/2 and Sup35 were the same in [psi–] and [PSI+] yeast (Supplemental Figure S5), as well as immediately before immunocapture (Figure 3). Similarly, Ssa1/2 preferentially interacted with the prion, but not the nonprion form of Sup35 in wild-type SUP35 yeast without plasmid (Figure 3B), ruling out the possibility that this preferential interaction of Ssa1/2 with the prion form of Sup35 was caused by the presence of the his6 tag or that it was dependent on the source of the SUP35 gene (plasmid vs. genomic).
|
Together, our data suggest that Ssa1/2 efficiently interacts with the prion, but not the nonprion form of the N-terminal domain of Sup35, and that it accounts for almost a third of total [PSI+] aggregate weight. We note that Ssa1/2 is almost 8 times more abundant than Sup35 in yeast lysates (Ghaemmaghami et al., 2003
); thus, even in [PSI+] cells, the majority of Ssa1/2 should be available for other interactions.
Some Minor Components of [PSI+] Aggregates Interact Poorly with Nonprion Sup35
To check whether minor components of [PSI+] aggregates interact with Sup35 in a prion-dependent manner, we performed immunocapture experiments from whole unfractionated lysates of sup35
yeast expressing a hemagglutinin-tagged Sup35 (Sup35-HA) from a centromeric vector under the SUP35 promoter. As shown previously, the presence of the hemagglutinin tag does not affect the prion properties of Sup35 (DePace et al., 1998
). Consistent with our data presented here, Sup35-HA efficiently interacted with Ssa1/2 in [PSI+], whereas the interaction was less efficient in [psi–] (Figure 4). Interestingly, a similar pattern was detected for cochaperones Sse1 and Sis1 of Ssa1/2 and for Hsp104: these proteins efficiently interacted with Sup35 only in [PSI+]. Although we cannot rule out the possibility that these proteins interact with Sup35 in [psi–], they seem to do so less efficiently than in [PSI+]. In contrast, Ssb1/2 and Sla2 interacted with Sup35 equally well in [PSI+] and [psi–]. Using this method of immunocapture, we did not detect interaction with Ydj1 in either of the strains, although Ydj1 did copurify with Sup35 via metal affinity chromatography (Figure 2B).
|
90% pure Sup35 polymers without Ssa1/2 (Figure 5B). The sample was negatively stained with uranyl acetate and visualized by electron microscopy (Figure 5, C–E). Full-length Sup35 polymerized in vitro has the appearance of long
20- to 50-nm-wide fibers (Glover et al., 1997
4–20 Sup35 monomers (Supplemental Figure S1B), we expected them to have the appearance of short barrels rather than long fibers. Indeed, we observed
20-nm-wide "barrels" (Figure 5E) and larger structures ("bundles"), which seem to be composed of these barrels (Figure 5D). These structures looked remarkably similar to what prion polymers made of full-length recombinant Sup35 look like when obtained in the presence of guanosine triphosphate and Hsp104 (see figure 5E in Shorter and Lindquist, 2006
|
|
| DISCUSSION |
|---|
|
|
|---|
We also show that Ssa1/2 efficiently interacts with the prion, but not the nonprion form of the Sup35N(1-137) domain produced in a sup35
2-252 strain. Prionization profoundly refolds the N-terminal domain of Sup35 (Glover et al., 1997
), which may explain why the efficiency of Ssa1/2 binding to Sup35 depends on the prion status of Sup35.
Genetic interactions between Sup35 and Ssa1/2 documented previously (for review, see (Jones and Tuite, 2005
; True, 2006
) support the finding that Ssa1/2 is associated with [PSI+] aggregates. Inactivation of Ssa1/2 by mutations that promote substrate binding destabilizes [PSI+] (see Jung et al., 2000
; Jones and Masison, 2003
; Jones et al., 2004
; Hung and Masison, 2006
; Loovers et al., 2006
), whereas overexpression of Ssa1/2 1) causes Sup35 polymers to increase in length (Allen et al., 2005
); 2) protects [PSI+] from curing by overexpression of Hsp104 (Newnam et al., 1999
; Wegrzyn et al., 2001
), which presumably results in excessive shearing of Sup35 polymers (Shorter and Lindquist, 2006
); and 3) destabilizes [PSI+] variants with abnormally large aggregates (Borchsenius et al., 2001
; Borchsenius et al., 2006
). To explain these results, it was suggested (Allen et al., 2005
; Song et al., 2005
) that Ssa1/2 binds to the Sup35 prion and thus provides a steric hindrance to Hsp104, thereby inhibiting its shearing effect on Sup35 polymers, resulting in their increase in size. Here, we present support for this hypothesis by showing that [PSI+] aggregates contain Sup35 and Ssa1/2 in an
2:1 M ratio, and interact with Hsp104. The large amount of Ssa1/2 we found associated with Sup35 polymers makes it reasonable that Ssa1/2 could participate in prion propagation by shielding Sup35 polymers from the shearing activity of Hsp104, which seems not to require other components for this purpose, at least in vitro (Shorter and Lindquist, 2006
, but see Inoue et al., 2004
). Here, we provide the first evidence that Hsp104 indeed physically interacts with Sup35 in [PSI+] lysates. We show that like Ssa1/2, Hsp104 interacts with Sup35 in the [PSI+] form more efficiently than in the [psi–] form. Hsp104 was previously shown to catalyze the conversion of preamyloid Sup35 oligomers into mature Sup35 prion polymers (Shorter and Lindquist, 2004
). However, in our [psi–] cells not overexpressing Sup35 the concentration of these oligomers is expected to be low, which may explain why we did not detect an interaction between Hsp104 and Sup35 in [psi–].
Interaction between Sla2, a component of yeast cytoskeletal machinery (for review, see Toret and Drubin, 2006
), with Sup35N(1-113) in a two-hybrid assay, or with immobilized Sup35N(1-251) in [PSI+] lysate was shown previously (Ganusova et al., 2006
). We now show that Sla2, in contrast to Ssa1/2, interacts with Sup35 from [PSI+] and [psi–] with similar efficiency. Because deletion of SLA2 in [PSI+] yeast is lethal, it was not possible to directly assay whether Sla2 participates in [PSI+] induction in vivo (Ganusova et al., 2006
). Our finding that Sla2 interacts with Sup35 in [psi–] indicates that Sla2 may indeed play a role in [PSI+] induction, which is yet to be clarified.
We also show that Ssb1/2, a yeast ribosome-associated chaperone that usually acts as a [PSI+] antagonist (Chernoff et al., 1999
; Kushnirov et al., 2000b
; Chacinska et al., 2001
; Allen et al., 2005
, 2007
), interacts with Sup35 equally in [PSI+] and [psi–] cells. This finding extends previous data showing a Sup35–Ssb1/2 interaction (Allen et al., 2005
). Ssb1/2 could either recognize a site on Sup35 located outside the prion domain, or a motif within the prion domain regardless of the folding status of the domain. Regardless, our data suggest that the prion status of Sup35 does not significantly influence the Ssb1/2–Sup35 interaction.
The molecular composition of [PSI+] aggregates has some similarity to the composition of the aggregates of another yeast prion, [PIN+] (Sondheimer and Lindquist, 2000
; Derkatch et al., 2001
). Like [PSI+], [PIN+] aggregates are organized at two levels: SDS treatment of the aggregates dramatically reduces their weight and yields SDS-stable Rnq1-containing "subparticles" (probably, polymers of Rnq1) (Bagriantsev and Liebman, 2004
). Rnq1 interacts with Ssa1/2 and its cochaperone Sis1 in [PIN+], but not in [pin–] cells. Although the stoichiometry of the Rnq1–Ssa1/2 interaction is unknown, Rnq1 and Sis1 are present in the aggregates in almost equimolar amounts (Sondheimer et al., 2001
; Lopez et al., 2003
). We detected Sis1 only among the minor components of [PSI+] aggregates. Although we do not rule out the possibility that the difference in the abundance of Sis1 detected in association with [PSI+] and [PIN+] was due to dissimilarities in the experimental approaches, it seems likely that prion–chaperone interaction is specific and that it is defined by the prion-forming sequence and the adjacent region (e.g., the M domain of Sup35) of the protein. Changes in these sequences may trigger a functional recruitment of a specific chaperone. For example, overexpression of Sis1, which does not significantly affect propagation of a conventional [PSI+], destabilizes the chimeric prion [PSI+ps] (Kryndushkin et al., 2002
) formed in S. cerevisiae by a fusion of the C-terminal domain of S. cerevisiae Sup35 with the N-terminal prion domain of Sup35 from Pichia methanolica (Kushnirov et al., 2000a
). Overexpression of Ssa1 cures [URE3], but it generally stabilizes [PSI+] (Schwimmer and Masison, 2002
). Overexpression of Hsp104 cures [PSI+] (Chernoff et al., 1995
), some variants of [PSI+ps] (Kushnirov et al., 2000a
,b
), but not [URE3] (Moriyama et al., 2000
) or [PIN+] (Derkatch et al., 1997
). Thus, the presence of a chaperone in the prion aggregate is likely to reflect a specific functional interaction between the chaperone and the prion, rather than a nonspecific response of a protein quality control mechanism to the presence of a misfolded protein aggregate.
We show that an SDS-treated preparation of [PSI+] aggregates isolated from yeast expressing a full-length Sup35 is infectious and that it induces variant-specific [PSI+] when delivered to [psi–] cells. This suggests that variant-specific [PSI+] infection does not require the aggregates to be intact, and infection is transmitted by individual Sup35 polymers within the aggregates. Although both SDS-treated and untreated aggregates were infectious, SDS treatment (followed by a dilution of SDS to 0.001% before contact with cells; see Materials and Methods) elevated the efficacy of the variant-specific [PSI+] induction approximately twofold. The most plausible explanation of this observation is that each [PSI+] aggregate contains several infectious Sup35 polymers, which were released after SDS treatment, thereby increasing the number of the infectious entities. This observation is supported by our electron microscopy analysis of a preparation of Sup35 aggregates, which revealed the presence of
20-nm-wide barrel-shaped structures, as well as bundles, which seemed to be composed of these barrels. These structures are remarkably similar to the infectious polymers of Sup35 obtained in vitro in the presence of Hsp104 and GTP (i.e., in biologically relevant conditions; see figure 5E at 20' in Shorter and Lindquist, 2006
). As might be expected, because Sup35 in these in vitro experiments was polymerized for 8 h before the addition of Hsp104, the resulting Sup35 polymers looked longer and more branched, but otherwise similar to the Sup35 polymers we isolated directly from yeast. Our results suggest that Sup35 polymers interact in vivo and together with other proteins form [PSI+] aggregates. This aspect is important, because in the literature there is no proper distinction between Sup35 polymers and aggregates. Here, we clarify this issue and emphasize the difference between Sup35 polymers and aggregates.
Based on the data presented here and obtained previously, we suggest a model where [PSI+] aggregates are composed of interacting Sup35 polymers and other proteins, among which chaperones are the most abundant (Figure 7). This model hints at an intriguing possibility that [PSI+] can be propagated not only by the frequently discussed cleavage of a single Sup35 polymer by Hsp104, but also via dissociation of separate polymers. Uncovering such activity will further elucidate the mechanism of prion propagation.
|
| ACKNOWLEDGMENTS |
|---|
-Ssa1/2,
-Ssb1/2, and
-Sis1 antibodies. We also thank Drs. Colin Crist and Yoshikazu Nakamura (University of Tokyo, Tokyo, Japan), Dr. S. Inge-Vechtomov (St. Petersburg State University, St. Petersburg, Russia), Dr. Mick Tuite (University of Kent, Canterbury, United Kingdom), Dr. Susan Lindquist (Whitehead Institute for Biomedical Research, Cambridge, MA), Dr. Jonathan Weissman (University of California, San Francisco, San Francisco, CA), Dr. Jeffrey Brodsky (University of Pittsburgh, Pittsburgh, PA), Dr. David Drubin (University of California, Berkeley, Berkeley, CA), and Dr. Viravan Prapapanich for yeast strains, plasmids, and other antibodies. We thank Dr. Alexander B. Schilling at the RRC Proteomics and Informatics Services Facility (University of Illinois, Chicago, IL) for performing the mass spectrometry analysis, and the staff of the RRC Electron Microscopy Facility for technical assistance in the electron microscopic analysis. We also thank Dr. Liming Li (Northwestern University, Chicago, IL) and the members of the Liebman laboratory for helpful comments on the manuscript. This work was supported by a fellowship 0610115Z from American Heart Association (to S.N.B.) and National Institutes of Health grants MH-073156 (to J.E.R.) and GM-56350 (to S.W.L.). | Footnotes |
|---|
Address correspondence to: Susan W. Liebman (sueL{at}uic.edu)
| REFERENCES |
|---|
|
|
|---|
Allen, K. D., Wegrzyn, R. D., Chernova, T. A., Muller, S., Newnam, G. P., Winslett, P. A., Wittich, K. B., Wilkinson, K. D., and Chernoff, Y. O. (2005). Hsp70 chaperones as modulators of prion life cycle: novel effects of Ssa and Ssb on the Saccharomyces cerevisiae prion [PSI+]. Genetics 169, 1227–1242.
Aron, R., Higurashi, T., Sahi, C., and Craig, E. A. (2007). J-protein co-chaperone Sis1 required for generation of [RNQ+] seeds necessary for prion propagation. EMBO J 26, 3794–3803.[CrossRef][Medline]
Bagriantsev, S., and Liebman, S. W. (2004). Specificity of prion assembly in vivo: [PSI+] and [PIN+] form separate structures in yeast. J. Biol. Chem 279, 51042–51048.
Bagriantsev, S. N., Kushnirov, V. V., and Liebman, S. W. (2006). Analysis of amyloid aggregates using agarose gel electrophoresis. Methods Enzymol 412, 33–48.[Medline]
Bagriantsev, S. N., and Liebman, S. W. (2006). Modulation of Abeta42 low-n oligomerization using a novel yeast reporter system. BMC Biol 4, 32.[CrossRef][Medline]
Borchsenius, A. S., Muller, S., Newnam, G. P., Inge-Vechtomov, S. G., and Chernoff, Y. O. (2006). Prion variant maintained only at high levels of the Hsp104 disaggregase. Curr. Genet 49, 21–29.[CrossRef][Medline]
Borchsenius, A. S., Wegrzyn, R. D., Newnam, G. P., Inge-Vechtomov, S. G., and Chernoff, Y. O. (2001). Yeast prion protein derivative defective in aggregate shearing and production of new seeds. EMBO J 20, 6683–6691.[CrossRef][Medline]
Bradford, M. M. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem 72, 248–254.[CrossRef][Medline]
Bradley, M. E., and Liebman, S. W. (2003). Destabilizing interactions among [PSI+] and [PIN+] yeast prion variants. Genetics 165, 1675–1685.
Bradley, M. E., and Liebman, S. W. (2004). The Sup35 domains required for maintenance of weak, strong or undifferentiated yeast [PSI+] prions. Mol. Microbiol 51, 1649–1659.[CrossRef][Medline]
Bruce, M. E. (2003). TSE strain variation. Br. Med. Bull 66, 99–108.
Chacinska, A., Szczesniak, B., Kochneva-Pervukhova, N. V., Kushnirov, V. V., Ter-Avanesyan, M. D., and Boguta, M. (2001). Ssb1 chaperone is a [PSI+] prion-curing factor. Curr. Genet 39, 62–67.[CrossRef][Medline]
Chernoff, Y. O. (2007). Stress and prions: lessons from the yeast model. FEBS Lett 581, 3695–3701.[CrossRef][Medline]
Chernoff, Y. O., Derkach, I. L., and Inge-Vechtomov, S. G. (1993). Multicopy SUP35 gene induces de-novo appearance of psi-like factors in the yeast Saccharomyces cerevisiae. Curr. Genet 24, 268–270.[CrossRef][Medline]
Chernoff, Y. O., Galkin, A. P., Lewitin, E., Chernova, T. A., Newnam, G. P., and Belenkiy, S. M. (2000). Evolutionary conservation of prion-forming abilities of the yeast Sup35 protein. Mol. Microbiol 35, 865–876.[CrossRef][Medline]
Chernoff, Y. O., Lindquist, S. L., Ono, B., Inge-Vechtomov, S. G., and Liebman, S. W. (1995). Role of the chaperone protein Hsp104 in propagation of the yeast prion-like factor [PSI+]. Science 268, 880–884.
Chernoff, Y. O., Newnam, G. P., Kumar, J., Allen, K., and Zink, A. D. (1999). Evidence for a protein mutator in yeast: role of the Hsp70-related chaperone ssb in formation, stability, and toxicity of the [PSI+] prion. Mol. Cell Biol 19, 8103–8112.
Chernoff, Y. O., Uptain, S. M., and Lindquist, S. L. (2002). Analysis of prion factors in yeast. Methods Enzymol 351, 499–538.[Medline]
Collins, S. R., Douglass, A., Vale, R. D., and Weissman, J. S. (2004). Mechanism of prion propagation: amyloid growth occurs by monomer addition. PLoS Biol 2, e321.[CrossRef][Medline]
Crist, C. G., Nakayashiki, T., Kurahashi, H., and Nakamura, Y. (2003). [PHI+], a novel Sup35-prion variant propagated with non-Gln/Asn oligopeptide repeats in the absence of the chaperone protein Hsp104. Genes Cells 8, 603–618.[Abstract]
DePace, A. H., Santoso, A., Hillner, P., and Weissman, J. S. (1998). A critical role for amino-terminal glutamine/asparagine repeats in the formation and propagation of a yeast prion. Cell 93, 1241–1252.[CrossRef][Medline]